Vivoryon Therapeutics N.V. is advancing PQ912, a glutaminyl cyclase inhibitor, in the treatment of early Alzheimer's disease, specifically targeting Mild Cognitive Impairment (MCI) and mild dementia due to Alzheimer's Disease (AD). The global Alzheimer's disease therapeutics market is projected to grow significantly, driven by increasing prevalence and demand for effective treatments. PQ912's unique mechanism of action positions it competitively against existing therapies, particularly in a landscape where disease-modifying treatments are scarce. The completion of this Phase 2A trial provides critical data that may enhance investor confidence and attract potential partnerships or acquisition interest, especially if preliminary efficacy results are favorable.